R
Romulus Capital Management, LLC
+ 持有HIND
+0.00%
3个月收益率
$1.600
-0.029 (-1.84%)收盘时
Loading chart…
- 最高
- 1.660
- 开盘
- 1.660
- 成交量加权均价
- 1.61
- 成交量
- 19.77K
- 市值
- —
- 最低
- 1.570
- 成交额
- 31.83K
- 企业价值/息税折旧摊销前利润（TTM）
- -0.56
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology.
AI 分析 of Vyome Holdings Inc (HIND)
持有Currently, Vyome Holdings Inc (HIND) is not a good buy due to its extremely low RSI of 17.286, indicating oversold conditions, and a significant year-to-date change of -54.93%. While the analyst target suggests potential upside, the current financial instability and negative earnings reports raise concerns.
估值指标
Vyome Holdings Inc（HIND）当前预期市盈率为 0.00，5 年平均预期市盈率为 -8.15。
持有 HIND 的大户
事件时间线
资讯
5.009-14NewsfilterVyome Holdings Appoints New CFO Jerry Leonard
9.505-29seekingalphaVyome Holdings Reports Q1 Revenue of $31.59M
- 7.505-28Newsfilter
Vyome Partners with Impetis for JAK Inhibitors, Targeting $57B Market
- 9.503-26seekingalpha
Vyome Holdings Reports FY 2025 Financial Results
- 8.502-18Newsfilter
Vyome Publishes Preclinical Data for VT-1908
HIND 常见问题 —— 由 Alphio AI 解答
Vyome Holdings, Inc. is a clinical-stage healthcare holding company. The Company is focused on leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. Its clinical program VT1953 Gel is focused on cancer patients who are suffering from malignant fungating wounds (MFW). Its preclinical development program, VT1908, is a non-steroidal eye drop, which is focused on Uveitis. Its other business unit is focused on offering artificial intelligence (AI)-driven healthcare solutions across mental health and inflammation care, digital therapeutics and psychoneuroimmunology. It operates in the Healthcare sector.
Currently, Vyome Holdings Inc (HIND) is not a good buy due to its extremely low RSI of 17.286, indicating oversold conditions, and a significant year-to-date change of -54.93%. While the analyst target suggests potential upside, the current financial instability and negative earnings reports raise concerns.
社区
更多 ↗暂无帖子
注册或登录后参与讨论相关文章
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
本页仅供研究参考，不构成投资建议。模型可能出错。过往表现不代表未来结果。